SRS Medical competitors

Mr. Chapman began his career in the Department of Human Genetics at UCLA, where he contributed to the selection process and design of oligonucleotide arrays used to identify SNPs associated with multiple sclerosis. After leaving UCLA, Mr. Chapman worked in a commercial role with Genzyme Genetics, where his team was responsible for prenatal and preconception genetic testing revenues nearing $100 million. During his time at Genzyme, Mr. Chapman’s efforts reshaped the way medicine is practiced when he led Genzyme’s sales initiative into population screening for Fragile X Syndrome.

Business focused with demonstrable experience in leading growth orientated organizations Has strong management, strategic development and business development experience underpinned by extensive consulting and technical capability extending over a30+ year period. Has a track record of success at strategic levels in the Healthcare and Life Science sectors and at an operational level in successful delivery of commercial initiatives. It is largely down to this track record that Gavin established and led a $50M co-development with Lilly to create a new service organization targeted at improving clinical planning and trial design. At Unisys with the role of practice head, Gavin grew the practice from zero to a $100M P&L. Previously to Unisys, Gavin initiated and led 2 startup organizations and was a Principal Consultant at Cap Gemini. Over the last few years Gavin has used his skills and experiences to support Private Equity organizations to drive organizational profitability and equity growth. He has achieved this through 3 core activities 1. Create business and technology strategies, within Healthcare and Life sciences, that align market needs with organizational capabilities 2. Develop and execute operational plans, normally around technology platforms, and establish high performing team 3. Develop corporate development deal that add non-dilutional value to drive early exits or increased multiples High-level experiences: • Has held executive positions in startup, private and public, with demonstrable experience in driving growth and value creation • Has led global technology teams that delivered Analytics, Recruitment, Wearables, EHR, Genetics, direct-to-consumer apps and trial management solutions • Has led IT strategy for IQVIA and consulting engagements with GSK, AstraZeneca and EMEA • Developed and managed P&L’s of over $300M with 2500 FTE’s • Has led corporate deals for Lilly, Allscripts and IQVIA

Dave Amerson is a President and Chief Executive Officer at NEOTRACT INC and is based in United States.